文献速递功能神经外科

全面性与颈部肌张力障碍脑深部电刺激的成本-效用分析:巴西医疗保健视角

Cost-Utility Analysis of Deep Brain Stimulation for Generalized and Cervical Dystonia: A Perspective from Brazilian Healthcare.
PubMed 文献 · World Neurosurg · 2024-09-05

该研究从巴西公共卫生系统角度评估脑深部电刺激(DBS)治疗成人全面性与颈部肌张力障碍的成本-效果。系统评价纳入两项随机对照试验,显示DBS联合最佳临床实践(BCP)较单纯BCP临床改善更优。增量成本-效用比分别为全面性肌张力障碍1121.66美元、颈部肌张力障碍4556.50美元,多数模拟值低于巴西成本-效果阈值8146.64美元/质量调整生命年。

要点

  • DBS联合BCP较单纯BCP临床改善更优,基于两项随机对照试验。
  • 增量成本-效用比:全面性肌张力障碍1121.66美元,颈部肌张力障碍4556.50美元。
  • 1000次蒙特卡洛模拟中,99.9%的全面性肌张力障碍和74.2%的颈部肌张力障碍增量成本-效用比值低于巴西阈值8146.64美元/质量调整生命年。

核心结论

  • 从巴西公共卫生系统视角看,DBS联合BCP治疗全面性和颈部肌张力障碍相比单纯BCP似乎具有成本-效果。

研究设计与样本

  • 系统评价识别评估DBS治疗成人全面性和颈部肌张力障碍疗效的随机对照试验。
  • 两项成本-效用分析比较DBS联合BCP与单纯BCP的成本-效果。
  • Markov模型包括3种健康状态(无临床改善、临床改善和死亡),采用1年周期和终生时间跨度。
  • 研究使用单因素和概率敏感性分析。

主要发现

  • 两项随机对照试验(每种疾病各一项)显示,与假刺激相比,DBS临床改善更优。
  • 增量成本-效用比:全面性肌张力障碍为1121.66美元,颈部肌张力障碍为4556.50美元。
  • 效果折扣率和手术时年龄被识别为有影响的参数。
  • 在1000次蒙特卡洛模拟中,全面性肌张力障碍99.9%的增量成本-效用比值和颈部肌张力障碍74.2%的增量成本-效用比值低于巴西成本-效果阈值(8146.64美元/质量调整生命年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the Brazilian public national healthcare system, botulinum toxin type A has traditionally been the sole treatment option for patients with dystonia. However, as of October 2022, deep brain stimulation (DBS) garnered positive recommendations for the condition. This study aims to assess the cost-effectiveness of DBS in treating adults with generalized and cervical dystonia within the Brazilian healthcare context, considering its recent inclusion. METHODS: A systematic review identified randomized controlled trials assessing DBS efficacy in treating adults with generalized and cervical dystonia. Two cost-utility analyses compared the cost-effectiveness of DBS plus the best clinical practice (BCP) to BCP alone. Markov models, which included 3 health states (no clinical improvement, clinical improvement, and death), employed a 1-year cycle and a lifetime horizon. The study used both 1-way and probabilistic sensitivity analyses. RESULTS: Two randomized controlled trials, one for each condition, revealed superior clinical improvement with DBS when compared to sham simulation. The incremental cost-utility ratio was $ 1121.66 for generalized dystonia and $4556.50 for cervical dystonia. Effectiveness discount rates and age at surgery were identified as influential parameters. In 1000 Monte Carlo simulations, 99.9% of the incremental cost-utility ratio values for generalized dystonia and 74.2% for cervical dystonia fell below the cost-effectiveness threshold in Brazil ($8146.64 per quality-adjusted life year). CONCLUSIONS: From the perspective of the Brazilian public health system, the combination of DBS and BCP appears to be cost-effective for the treatment of both generalized and cervical dystonia when compared to BCP alone.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Nardi EP, Araújo Silva LC, Kawakami DY, et al. Cost-Utility Analysis of Deep Brain Stimulation for Generalized and Cervical Dystonia: A Perspective from Brazilian Healthcare. World Neurosurg. 2024. PMID: 39243964. doi:10.1016/j.wneu.2024.08.153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。